newsfilter
← Latest News
GlobeNewswire·

XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer

AUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ:XBIT) announced today the enrollment of the first patient in a multicenter, randomized clinical study for Natrunix in combination with